Format

Send to

Choose Destination
PLoS One. 2019 Dec 5;14(12):e0223515. doi: 10.1371/journal.pone.0223515. eCollection 2019.

Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.

Author information

1
Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, United States of America.
2
Department of Population Health Sciences, Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC, United States of America.
3
Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, United States of America.
4
HealthCore, Inc., Wilmington, DE, United States of America.
5
HealthPartners Institute, Minneapolis, MD, United States of America.

Abstract

BACKGROUND:

Data from randomized controlled trials and observational studies on older adults who take statins for primary prevention of atherosclerotic cardiovascular disease are limited. To determine the incidence of statin use in older adults with and without cardiovascular disease (CVD) and/or diabetes (DM), we conducted a descriptive observational study.

METHODS:

The cohort consisted of health plan members in the NIH Collaboratory Distributed Research Network aged >75 years who had continuous drug and medical benefits for ≥183 days during the study period, January 1, 2008- March 31, 2018. We defined DM and CVD using diagnosis codes, and identified statins using dispensing data. Statin use was considered incident if a member had no evidence of statin exposure in the claims during the previous 183 days, and the use was considered long-term if statins were supplied for ≥180 days. Incidence rates were reported among members with and without CVD and/or diabetes, and stratified by year, sex, and age group.

RESULTS:

Among 757,569 eligible members, 109,306 older adults initiated statins and 54,624 became long-term users. Health plan members with CVD had the highest incidence of statin use (143.9 initiators per 1,000 member-years for CVD & DM; 114.5 initiators per 1,000 member-years for CVD & No DM). Among health plan members without CVD, those with DM had rates of statin use that were over two times higher than members without DM (76.1 versus 34.5 initiators per 1,000 member-years, respectively). Statin initiation remained steady throughout 2008-2016, was slightly higher in males, and declined with increasing age.

CONCLUSION:

Incidence of statin use varied by CVD and DM comorbidity, and was lowest among those without CVD. These results highlight the potential clinical equipoise to conduct large pragmatic clinical trials to generate evidence that could be used to inform future blood cholesterol guidelines.

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: One of the authors [KH] is employed by HealthCore, Inc. Dr. Curtis has research contracts with Glaxo Smith Kline, Medtronic, and Novartis. None of the work is related to this manuscript. Dr. Hernandez consults and conducts research for AstraZeneca, Merck, and Novartis. He consults for Bayer. The other authors have declared that no competing interests exist. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center